Federico Cucchiara
Overview
Explore the profile of Federico Cucchiara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crucitta S, Cucchiara F, Marconcini R, Bulleri A, Manacorda S, Capuano A, et al.
Front Mol Biosci
. 2024 Apr;
11:1288677.
PMID: 38633217
Immune checkpoint inhibitors (ICIs) represent the standard therapy for metastatic melanoma. However, a few patients do not respond to ICIs and reliable predictive biomarkers are needed. This pilot study investigates...
2.
Pardini E, Cucchiara F, Palumbo S, Tarrini G, Di Vita A, Coppede F, et al.
Front Oncol
. 2023 Sep;
13:1224491.
PMID: 37671056
Background: Thymic epithelial tumors are rare malignant neoplasms that are frequently associated with paraneoplastic syndromes, especially myasthenia gravis. GTF2I is an oncogene mutated in a subgroup of thymomas that is...
3.
Cucchiara F, Crucitta S, Petrini I, Perez D, Ruglioni M, Pardini E, et al.
Lung Cancer
. 2023 Jul;
183:107308.
PMID: 37473500
Objectives: Predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have been extensively studied in non-small cell lung cancer (NSCLC) with controversial results. Recently, gene-network analysis emerged as a new...
4.
Lorenzini G, Cucchiara F, Pennati P
Intern Emerg Med
. 2023 May;
18(8):2333-2337.
PMID: 37148408
No abstract available.
5.
Crucitta S, Ruglioni M, Novi C, Manganiello M, Arici R, Petrini I, et al.
Clin Chim Acta
. 2023 Feb;
541:117239.
PMID: 36736684
Background And Aims: Highly sensitive technologies are available for the molecular characterization of solid tumors, including digital PCR (dPCR). Liquid biopsy, based on the analysis of cell-free DNA (cfDNA), is...
6.
Borelli B, Crucitta S, Boccaccino A, Antista M, Antoniotti C, Marmorino F, et al.
Tumori
. 2023 Jan;
109(5):481-489.
PMID: 36609197
Background: Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients' refractory to standard chemotherapy. No prognostic or predictive biomarkers are available for these agents. Methods: We assessed messenger...
7.
Del Re M, Crucitta S, Paolieri F, Cucchiara F, Verzoni E, Bloise F, et al.
J Transl Med
. 2022 Aug;
20(1):371.
PMID: 35974365
Background: Despite the increasing number of treatment options, reliable prognostic/predictive biomarkers are still missing for patients affected by metastatic clear cell renal cell carcinoma (mccRCC). Methods: Patients with mccRCC undergoing...
8.
Fornaro L, Musettini G, Orlandi P, Pecora I, Vivaldi C, Banchi M, et al.
Am J Cancer Res
. 2022 Aug;
12(7):3347-3356.
PMID: 35968330
Ramucirumab plus paclitaxel is considered the standard of care in the second-line treatment of gastric carcinoma (GC). The aim of this study was to evaluate plasma vascular endothelial growth factor-A...
9.
Cucchiara F, Petrini I, Passaro A, Attili I, Crucitta S, Pardini E, et al.
Clin Lung Cancer
. 2022 Jun;
23(6):510-521.
PMID: 35739016
Background: Small cell lung cancer (SCLC) is an aggressive tumor, and despite its sensitivity to chemotherapy and radiotherapy, patients usually have a short survival. There are no clinically relevant predictive...
10.
Cucchiara F, Luci G, Giannini N, Giorgi F, Orlandi P, Banchi M, et al.
Pharmacol Res
. 2022 Jun;
181:106290.
PMID: 35680010
Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV). This study is aimed at associating progression-free survival (PFS) and...